Streptokinase in Acute Myocardial Infarction — Benefits and Risks

  • H. Schmutzler
Part of the Supplement zu den Sitzungsberichten der Mathematisch-naturwissenschaftlichen Klasse Jahrgang 1988 book series (HD AKAD, volume 1988 / 1988/2)


Thirty years ago in 1958 the first experience with intravenous administration of fibrinolytic agents in 22 patients with acute myocardial infarction was reported by Fletcher and coworkers in the United States [6]. The next step was intermittent diastolic administration of fibrinolysin through a catheter in Valsalva’s sinus in 1960, reported by Boucek and Murphy [1]. In the period between 1960 and 1966 uncontrolled and controlled studies were reported, involving intravenous administration of streptokinase with initial dose of 250×103 U followed by maintenance doses of 100×103 U/h for periods of 12–24 h in patients with acute myocardial infarction. As a result, successful treatment by thrombolysis or fibrinolysis was suspected but not proven in individual cases. Although all investigators recognized the necessity of coronary angiography, prevailing opinion at that time held that angiography in the setting of acute infarction was associated with unacceptably high risk. Randomized and controlled multicenter studies with large groups of patients were initiated to allow statistical analysis of mortality in this situation.


Acute Myocardial Infarction Thrombolytic Therapy Thrombolytic Agent Myocardial Salvage Fibrinolytic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boucek RJ, Murphy WP (1960) Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Am J Cardiol 6: 525PubMedCrossRefGoogle Scholar
  2. 2.
    Braunwald E (1983) Thrombolytic therapy in patients with acute myocardial infarction. Summary and comments. Circulation 68 [Suppl 1]: 67–69Google Scholar
  3. 3.
    Chazov EJ, Matveeva LS, Mazaev AV, Ruda MY (1975) Intracoronary administration of fibrolysin in myocardial infarction. Therapy-Archiv Kardiolog. Fragen 48: 7Google Scholar
  4. 4.
    Erbel R, Pop T, Heinrichs KJ, von Olshausen K, Schuster CJ, Rupprecht HJ, Steuernagel C, Meyer J (1986) Percutaneous transluminal coronary angioplasty after thrombolytic therapy: a prospective controlled randomized trial. J Am Coll Cardiol 8 [3]: 485–495PubMedCrossRefGoogle Scholar
  5. 5.
    DeWood MA, Spores J, Notske R et al. (1980) Prevalence of total coronary occlusion during the early hours of transluminal myocardial infarction. N Engl J Med 303: 897–902PubMedCrossRefGoogle Scholar
  6. 6.
    Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S (1958) The treatment of patients suffering from early myocardial infarction by massive and prolonged streptokinase therapy. Tr Assoc Am Physicians 71: 287Google Scholar
  7. 7.
    Hugenholtz PG (1987) Acute coronary artery obstruction in myocardial infarction: overview of thrombolytic therapy. J Am Coll Cardiol 9 [6]: 1375–1384PubMedCrossRefGoogle Scholar
  8. 8.
    Miller HI, Almagor J, Keren G, Chernilas J, Roth A, Eschar Y, Shapira I, Shagorodsky B, Berenfeld D, Laniado S (1987) Early intervention in acute myocardial infarction: significance for myocardial salvage of immediate intravenous streptokinase therapy followed by coronary angioplasty. J Am Coll Cardiol 9 [3]: 608–614PubMedCrossRefGoogle Scholar
  9. 9.
    Patel B, Kloner RA (1987) Analysis of reported randomized trials of streptokinase therapy for acute myocardial infarction in the 1980s. Am J Cardiol 59: 501–504PubMedCrossRefGoogle Scholar
  10. 10.
    Rentrop P, De Vivie ER, Karsch KR, et al. (1978) Acute coronary occlusion with impending infarction as an angiographie complication relieved by a guide wire recanalization. Clin Cardiol 1: 101–107PubMedCrossRefGoogle Scholar
  11. 11.
    Rutsch W, Jatzkewitz A, Schartl M, Eichstädt H, Schmutzler H (1985) One-year follow-up after thrombolytic therapy in acute myocardial infarction. Eur Heart J 6: 187–192CrossRefGoogle Scholar
  12. 12.
    Rutsch W, Schartl M, Schmutzler H (1986) Percutaneous transluminal angioplasty in acute myocardial infarction with and without prior systemic fibrinolytic therapy. In: Höfling B (ed) Current problems in PTCA. Steinkopff, DarmstadtGoogle Scholar
  13. 13.
    Rutsch W, Schmutzler H (1986) Intracoronary thrombolysis: organizational prerequisites, technique, and results. Cardiovasc Intervent Radiol 9: 245–252PubMedCrossRefGoogle Scholar
  14. 14.
    Rutsch W, Schartl M, Schmutzler H (1987) Die Europäischen rt-PA-Studien beim akuten Myokardinfarkt. In: De Bono DP, Bronchier ML, Hugenholtz P, Kübler W, Verstraete M (eds) Thrombolytische Therapie des akuten Herzinfarktes. Springer, Berlin Heidelberg New York, p 75CrossRefGoogle Scholar
  15. 15.
    Sheehan FH (1987) Determinants of improved left ventricular function after thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 9 [4]: 937–944PubMedCrossRefGoogle Scholar
  16. 16.
    Sherry S (1987) Recombinant tissue plasminogen activator (rt-PA): Is it the thrombolytic agent of choice for an evolving acute myocardial infarction? Am J Cardiol 59: 984–989PubMedCrossRefGoogle Scholar
  17. 17.
    Schmutzler H, Rutsch W, Schartl M, Eichstädt H, Jatzkewitz A (1986) Langzeitergebnisse nach Therapie mit Streptokinase bei Myokardinfarkt. Herz 11 [1]: 1–8PubMedGoogle Scholar
  18. 18.
    Schmutzler R, Heckner F, Körtge P, van Deloo J, Pezold FA, Poliwoda H, Praetorius TF, Zekorn D (1966) Zur thrombolytischen Therapie des frischen Herzinfarktes. (I. deutsch-schweizerische Studie) Dtsch Med Wochenschr 91: 581PubMedCrossRefGoogle Scholar
  19. 19.
    The TIMI Study Group (1985) Special report. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med: 932–936Google Scholar
  20. 20.
    Timmis AD, Griffin B, Crick JCP, Sowton E (1987) Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study. J Am Coll Cardiol 10 [1]: 205–210PubMedCrossRefGoogle Scholar
  21. 21.
    Tognoni F, Rovelli F et al. for GISSI (Gruppo Italiano per lo Studio della streptochinasi nell’infarcto myocardio) (1986) Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet I: 397–402Google Scholar
  22. 22.
    Topoi EJ, Morris DC, Smalling RW, Schumacher RR, Taylor CR, Nishikawa A, Liberman HA, Collen D, Tufte ME, Grossbard EB, O’Neill WW (1987) A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-plasminogen activator (activase) in acute myocardial infarction. J Am Coll Cardiol 9: 1205–1213CrossRefGoogle Scholar
  23. 23.
    Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O’Neill WW (1987) A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 10 [317]: 581–588CrossRefGoogle Scholar
  24. 24.
    Verstraete M, Bernard R, Bory M, et al. (1985) Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet I: 842–847CrossRefGoogle Scholar
  25. 25.
    Verstraete M, Arnold AER, Brower RW, Collen D, de Bono DP, de Zwaan C, Erbel R, Hillis WS, Lennane RJ, Lubsen J, Mathey D, Reid DS, Rutsch W, Schartl M, Schofer J, Serruys PW, Simoons ML, Uebis R, Vahanian A, Verheugt FA, von Essen R (1987) Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. Arti J Cardiol 60: 231–237CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • H. Schmutzler

There are no affiliations available

Personalised recommendations